Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
NCT04305444 · Zhejiang DTRM Biopharma · PHASE2 · terminated · last registry update 2025-01-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Despite the efforts of our dedicated team and initial progress, we were unable to secure the necessary financial resources to continue the study. We appreciate the support and participation of all involved.” | – | Registry record, Zhejiang DTRM Biopharma |
Also happening at the time. Not shown to be a cause.
No drug target was found for this trial's interventions, so there is no same-target timeline.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision